Bifalgorithm post · ASCO 2026: Studies Aim to Expand Treatment Options for Lung Cancer · ROSETTA Lung-02: Pumitamig

Trial Design

Trial Design (ASCO 2026: Studies Aim to Expand Treatment Options for Lung Cancer · ROSETTA Lung-02: Pumitamig) — "In this phase 2/3 study (NCT06712316), 23 pat…

Ideas in this flowchart

  • The phase 2/3 ROSETTA Lung-02 study evaluated pumitamig-based treatment in untreated nonsquamous NSCLC.
  • The study was identified as NCT06712316.
  • Twenty-three patients were randomly assigned to pumitamig 1400 mg or 2000 mg.
  • Both pumitamig groups also received carboplatin AUC5 plus pemetrexed 500 mg/m2.
  • Another 21 patients were randomly assigned to pumitamig 1400 mg or 2000 mg with chemotherapy.
  • These groups received carboplatin AUC6 plus paclitaxel 200 mg/m2.
  • Across all four groups, patients had stage IIIB/IIIC or IV disease and had not previously received systemic treatment.
  • The phase 3 portion is recruiting for first-line treatment of squamous and nonsquamous-cell NSCLC.
  • Dr Peters reported the ongoing phase 3 recruitment.
Bifalgorithm
Sign up
Feed/

Trial Design

No cover

Channel

ASCO 2026: Studies Aim to Expand Treatment Options for Lung Cancer

1 page

U
USR292600b83e2a
Ebook2w

"In this phase 2/3 study (NCT06712316), 23 patients with nonsquamous NSCLC were randomly assigned to receive pumitamig 1400 mg or 2000 mg; both groups also received carboplatin (AUC5) plus pemetrexed (500 mg/m2). Another 21 patients were randomly assigned to receive pumitamig 1400 mg or 2000 mg plus carboplatin (AUC6) and paclitaxel (200 mg/m2). All patients across the 4 groups had stage IIIB/IIIC or IV disease and were not previously exposed to systemic treatment.\n\nThe phase 3 portion of the ROSETTA Lung-02 trial is now recruiting for first-line treatment of squamous and nonsquamous-cell NSCLC, Dr Peters said."

Flowchart preview
👍
0
0 comments0 shares

Sign in to view and post comments.